Talaat Al Shuqairat, MD
Pulmonary Disease · Salem, UTNPI 1104875574
Payments from drug & device makers
Across 1,158 payments — averaging $213.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$143K
- Mylan Specialty L.p.$40K
- AstraZeneca$19K
- United Therapeutics Corporation$9K
- Verona Pharma, Inc.$8K
- Intuitive Surgical$8K
- plus $21K from 46 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$247,629 in reported general payments places this provider in the 90th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Salem
- Mary ScholandSalt Lake City$3M
- Ithan PeltanMurray$1.1M
- Mark DodsonMurray$601K
- Lynette BrownMurray$273K
- Mark MartinezSalt Lake City$261K
- Erin BlackstockSalt Lake City$249K
- Samuel BrownMurray$232K
- Timothy LeclairMurray$182K
- Meghan CirulisMurray$137K
- Jason CarrSalt Lake City$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.